SynthesisFrontiers in pain research (Lausanne, Switzerland)2026
Fibromyalgia in cancer patients: a systematic review and clinical implications for integrated care.
Synthesis in Frontiers in pain research (Lausanne, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: In oncology, fibromyalgia (FM) is increasingly recognized as a clinically relevant comorbidity, as cancer patients frequently present overlapping symptoms such as pain, fatigue, and sleep disturbances, complicating clinical assessment and management. Moreover, anticancer treatments may trigger or exacerbate FM-like symptoms. This systematic review aimed to synthesize the available evidence on FM in oncological patients, focusing on prevalence, clinical characteristics, and its impact on pain perception, Health-Related Quality of Life (HRQoL), and treatment adherence. Methods: A comprehensive literature search was conducted in PubMed, Embase, and Scopus, including studies published from 2014 to 2024. Eligible studies, in accordance with PRISMA guidelines, included observational, cross-sectional and interventional designs involving adult patients with FM in the context of cancer or cancer-related pain. Conversely, studies not assessing FM in relation to cancer or cancer-related pain were excluded. Risk of bias was evaluated using ROBINS-I tool and the RoB 2 tool. Results: A total of 11 studies were included, encompassing heterogeneous populations and study designs, thereby precluding a quantitative synthesis of the literature. Overall, evidence suggests that FM did not increase cancer risk but significantly contributes to pain amplification, higher symptom burden, reduced HRQoL, and impaired treatment adherence. Pre-existing nociplastic pain features were associated with premature discontinuation of oncological therapies, particularly endocrine treatments. The substantial overlap between FM-related and cancer-related symptoms may represent a major diagnostic challenge in clinical practice. Discussion: This review highlights a substantial research gap, as evidence in oncology populations remains limited and is affected by moderate to high risk of bias, partly due to confounding factors. Nevertheless, FM appears to be a relevant comorbidity in oncology, warranting further investigation. High-quality longitudinal studies are needed to clarify causal associations and support evidence-based management. Systematic Review Registration: The protocol for this systematic review was retrospectively registered on the Open Science Framework (OSF; https://doi.org/10.17605/OSF.IO/X5N29).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.